We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





New Sensitive Blood Assay Detects Tuberculosis Antigen Directly in Blood

By LabMedica International staff writers
Posted on 29 Jul 2026

Tuberculosis continues to be a leading global infectious disease, and diagnosis still hinges on sputum samples that many patients cannot produce early in illness. More...

Delays in confirming Mycobacterium tuberculosis facilitate transmission and complicate management. A blood-based method that separates exposure states and detects active disease could accelerate triage when sputum testing is limited. New findings presented at the ADLM 2026 meeting ooutline a sensitive approach that measures a bacterial antigen in blood to identify active tuberculosis.

Taipei Veterans General Hospital investigators evaluated a blood assay that quantifies a biomarker called circulating 6‑kDa early secreted antigenic target (ESAT‑6) with a new biosensor. ESAT‑6 is derived directly from M. tuberculosis. This differentiates it from immune-response biomarkers.

The researchers measured ESAT-6 in blood from 217 participants classified as cases, defined as active pulmonary tuberculosis, or controls. The control groups included patients with lung disease caused by non-tuberculosis Mycobacterium species, patients with lung cancer, individuals with latent tuberculosis after exposure, uninfected exposed contacts, and healthy individuals with no known contacts. Together, the samples represented a spectrum of exposure and disease states.

ESAT-6 effectively distinguished tuberculosis from non-tuberculosis groups and increased stepwise from uninfected exposed contacts to latent infection to active disease. This association persisted after accounting for age, sex, and diabetes, and the marker outperformed two common blood-based markers. Findings were presented July 28, 2026, in Anaheim, California, as Abstract A-097 during the scientific poster session.

“Every week of delay in diagnosing TB matters — so early identification may allow treatment to begin sooner and potentially reduce transmission,” said Dr. Sheng‑Wei Pan, a physician in the department of chest medicine at Taipei Veterans General Hospital in Taiwan and the study’s lead author.

“We are currently planning a prospective study to further evaluate if this can be used in a real‑world clinical setting,” added Dr. Pan.

Related Links
Taipei Veterans General Hospital
 


Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
Manual Pipetting Aid
Pipette Controllers macro
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Graphical Abstract (Morgane Fournier et al., Cell (2026). DOI: 10.1016/j.cell.2026.04.013)

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.